Decrease In Funding For Medical Research Can Have Serious Results
08/04/2015 07:25
Decrease In Funding For Medical Research Can Have Serious Results.
Spending on medical study is waning in the United States, and this shift could have dire consequences for patients, physicians and the fitness care industry as a whole, a new analysis reveals. America is losing territory to Asia, the research shows virilityex. And if left unaddressed, this decline in spending could mug the world of cures and treatments for Alzheimer's disease, diabetes, depression and other conditions that thorn in one's side the human race, said lead author Dr Hamilton Moses III, collapse and chairman of the Alerion Institute, a Virginia-based think tank.
A great expansion in medical research that began in the 1980s helped revolutionize cancer proscription and treatment, and turned HIV/AIDS from a fatal affliction to a chronic condition. But between 2004 and 2012, the rate of investment growth declined to 0,8 percent a year in the United States, compared with a increase rate of 6 percent a year from 1994 to 2004, the backfire notes. "Common diseases that are devastating are not receiving as much of a push as would be occurring if the earlier take to task of investment had been sustained".
America now spends about $117 billion a year on medical research, which is about 4,5 percent of the nation's totality health care expenses, the researchers report Jan 13, 2015 in the Journal of the American Medical Association. Cuts in direction funding are the out-and-out cause for flagging investment in research, they found. Meanwhile, the share of US medical research funding from sequestered industry has increased to 58 percent in 2012, compared with 46 percent in 1994.
This has caused the United States' perfect share of global research funding - both catholic and private - to decline from 57 percent in 2004 to 44 percent in 2012, the reveal noted. While the United States still maintains its preeminence in medical research, Asian countries forebode to take the lead. Asia - particularly China - tripled investment from $2,6 billion in 2004 to $9,7 billion in 2012, according to the report.
So "There's no subject we should be responsible about the US decline in global investment for medical research," said Dr Victor Dzau, president of the Institute of Medicine of the National Academy of Sciences, who wrote an accompanying editorial. "In the manipulation we're going, we're current to lose our innovation and competitiveness globally". Signs of slippage are beginning to show, the authors noted. China filed 30 percent of far-reaching pep science patent applications in 2011, compared with 24 percent from the United States.
From 1981 to 2011, the pay out of "highly valuable" patents filed in the United States by American inventors decreased from 73 percent to 59 percent, while all other countries analyzed increased their share. Losing the foot-race to palpable new medical technologies could cost Americans tremendously. "Scientists care for to believe that science done anywhere can be applied anywhere, but in patented advances, the mobility across borders is often restricted due to contention of those rights. If China or Singapore or India patents their innovations promiscuously and widely, it may guide applications, and certainly would increase the cost of those applications".
Although the reduction in government spending has led to this decline, Moses does not take it the solution lies in the federal government. Instead, the authors push a series of potential new funding sources, including: Changes to tax laws that would appropriate companies to bring money now in offshore accounts back into the United States, provided the legal tender goes to research. "If you took 10 percent of repatriated funds, you could double, triple, quadruple the change available to research". The creation of "biomedical research bonds" floated by federal, nation and local governments, similar to those used to finance airports and sports stadiums. Research invention trusts that would encourage public-private partnerships in medical research, with investors receiving encumbrance credits. Tax checkoffs that would allow people to specify a portion of their annual taxes go to medical research. California, Maryland, New York and Oregon already have made information a priority using c tithe checkoffs, the authors note.
And "America has not lost its way in research. We are the scientific chieftain by any measurement in the world. It would be ideal if the United States would maintain its momentum by bolstering its funding". Dzau called for a remodelled strategic vision for research in the United States. "Whatever check in and development we do, we lack an overall view of where we need to be coffee. We need a national blueprint and a more predictable budget".
Spending on medical study is waning in the United States, and this shift could have dire consequences for patients, physicians and the fitness care industry as a whole, a new analysis reveals. America is losing territory to Asia, the research shows virilityex. And if left unaddressed, this decline in spending could mug the world of cures and treatments for Alzheimer's disease, diabetes, depression and other conditions that thorn in one's side the human race, said lead author Dr Hamilton Moses III, collapse and chairman of the Alerion Institute, a Virginia-based think tank.
A great expansion in medical research that began in the 1980s helped revolutionize cancer proscription and treatment, and turned HIV/AIDS from a fatal affliction to a chronic condition. But between 2004 and 2012, the rate of investment growth declined to 0,8 percent a year in the United States, compared with a increase rate of 6 percent a year from 1994 to 2004, the backfire notes. "Common diseases that are devastating are not receiving as much of a push as would be occurring if the earlier take to task of investment had been sustained".
America now spends about $117 billion a year on medical research, which is about 4,5 percent of the nation's totality health care expenses, the researchers report Jan 13, 2015 in the Journal of the American Medical Association. Cuts in direction funding are the out-and-out cause for flagging investment in research, they found. Meanwhile, the share of US medical research funding from sequestered industry has increased to 58 percent in 2012, compared with 46 percent in 1994.
This has caused the United States' perfect share of global research funding - both catholic and private - to decline from 57 percent in 2004 to 44 percent in 2012, the reveal noted. While the United States still maintains its preeminence in medical research, Asian countries forebode to take the lead. Asia - particularly China - tripled investment from $2,6 billion in 2004 to $9,7 billion in 2012, according to the report.
So "There's no subject we should be responsible about the US decline in global investment for medical research," said Dr Victor Dzau, president of the Institute of Medicine of the National Academy of Sciences, who wrote an accompanying editorial. "In the manipulation we're going, we're current to lose our innovation and competitiveness globally". Signs of slippage are beginning to show, the authors noted. China filed 30 percent of far-reaching pep science patent applications in 2011, compared with 24 percent from the United States.
From 1981 to 2011, the pay out of "highly valuable" patents filed in the United States by American inventors decreased from 73 percent to 59 percent, while all other countries analyzed increased their share. Losing the foot-race to palpable new medical technologies could cost Americans tremendously. "Scientists care for to believe that science done anywhere can be applied anywhere, but in patented advances, the mobility across borders is often restricted due to contention of those rights. If China or Singapore or India patents their innovations promiscuously and widely, it may guide applications, and certainly would increase the cost of those applications".
Although the reduction in government spending has led to this decline, Moses does not take it the solution lies in the federal government. Instead, the authors push a series of potential new funding sources, including: Changes to tax laws that would appropriate companies to bring money now in offshore accounts back into the United States, provided the legal tender goes to research. "If you took 10 percent of repatriated funds, you could double, triple, quadruple the change available to research". The creation of "biomedical research bonds" floated by federal, nation and local governments, similar to those used to finance airports and sports stadiums. Research invention trusts that would encourage public-private partnerships in medical research, with investors receiving encumbrance credits. Tax checkoffs that would allow people to specify a portion of their annual taxes go to medical research. California, Maryland, New York and Oregon already have made information a priority using c tithe checkoffs, the authors note.
And "America has not lost its way in research. We are the scientific chieftain by any measurement in the world. It would be ideal if the United States would maintain its momentum by bolstering its funding". Dzau called for a remodelled strategic vision for research in the United States. "Whatever check in and development we do, we lack an overall view of where we need to be coffee. We need a national blueprint and a more predictable budget".